<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Teva Pharmaceutical Industries Ltd — News on 6ix</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd</link>
<description>Latest news and press releases for Teva Pharmaceutical Industries Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/teva-pharmaceutical-industries-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836282478dffbe2df1444c3.webp</url>
<title>Teva Pharmaceutical Industries Ltd</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd</link>
</image>
<item>
<title>Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-launches-home-groundtm-schizophrenia-community-a-new-online-resource-hub-for-people-living-with-schizophrenia-and-their-care-partners</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-launches-home-groundtm-schizophrenia-community-a-new-online-resource-hub-for-people-living-with-schizophrenia-and-their-care-partners</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools and connection Home Ground™ was developed in collaboration with people living with schizophrenia, care partners and mental health advocacy groups to help support wellbeing through shared experienceAs a leader in neuroscience, Teva is committed to supporting peopl</description>
</item>
<item>
<title>Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-and-charitable-clinics</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-and-charitable-clinics</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communitiesSANTA BARBARA, Calif. and PARSIPPANY, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics (NAFC) today announced a second round of grant funding in the amount of $75,000 to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas. Orig</description>
</item>
<item>
<title>Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-gains-biosimilar-momentum-with-us-fda-approval-of-ponlimsitm-denosumab-adet-and-dual-filing-acceptance-for-biosimilar-candidate-to-xolairr-omalizumab</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-gains-biosimilar-momentum-with-us-fda-approval-of-ponlimsitm-denosumab-adet-and-dual-filing-acceptance-for-biosimilar-candidate-to-xolairr-omalizumab</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA.These milestones demonstrate Teva’s biosimilars expertise and are a significant step in Teva’s Pivot to Growth strategy, highlighting its transformation into a leading biopharmaceutical company with a broad biosimilars por</description>
</item>
<item>
<title>Teva Releases Q1 2026 Aide Memoire</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-releases-q1-2026-aide-memoire</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-releases-q1-2026-aide-memoire</guid>
<pubDate>Thu, 19 Mar 2026 20:30:00 GMT</pubDate>
<description>TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am</description>
</item>
<item>
<title>Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-host-conference-call-to-discuss-first-quarter-2026-financial-results-at-8-am-et-on-april-29-2026</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-host-conference-call-to-discuss-first-quarter-2026-financial-results-at-8-am-et-on-april-29-2026</guid>
<pubDate>Thu, 19 Mar 2026 20:30:00 GMT</pubDate>
<description>TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your person</description>
</item>
<item>
<title>Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-blackstone-life-sciences-announce-dollar400-million-strategic-growth-capital-agreement-to-advance-duvakitug-23</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-blackstone-life-sciences-announce-dollar400-million-strategic-growth-capital-agreement-to-advance-duvakitug-23</guid>
<pubDate>Tue, 03 Mar 2026 22:00:00 GMT</pubDate>
<description>Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD)Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.</description>
</item>
<item>
<title>Teva to Present at the Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-upcoming-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-upcoming-investor-conferences-in-march</guid>
<pubDate>Tue, 24 Feb 2026 21:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global H</description>
</item>
<item>
<title>U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/us-food-and-drug-administration-fda-accepts-tevas-new-drug-application-nda-for-olanzapine-extended-release-injectable-suspension-tev-749-for-the-once-monthly-treatment-of-schizophrenia-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/us-food-and-drug-administration-fda-accepts-tevas-new-drug-application-nda-for-olanzapine-extended-release-injectable-suspension-tev-749-for-the-once-monthly-treatment-of-schizophrenia-in-adults</guid>
<pubDate>Fri, 20 Feb 2026 19:43:00 GMT</pubDate>
<description>Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex ne</description>
</item>
<item>
<title>Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-sanofis-duvakitug-phase-2b-maintenance-data-demonstrated-clinically-meaningful-durable-efficacy-in-ulcerative-colitis-and-crohns-disease</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-sanofis-duvakitug-phase-2b-maintenance-data-demonstrated-clinically-meaningful-durable-efficacy-in-ulcerative-colitis-and-crohns-disease</guid>
<pubDate>Tue, 17 Feb 2026 11:00:00 GMT</pubDate>
<description>In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS</description>
</item>
<item>
<title>Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-canada-announces-approval-of-expanded-indication-of-prajovyr-fremanezumab-solution-for-subcutaneous-injection-the-first-anti-cgrp-preventive-treatment-for-pediatric-episodic-migraine</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-canada-announces-approval-of-expanded-indication-of-prajovyr-fremanezumab-solution-for-subcutaneous-injection-the-first-anti-cgrp-preventive-treatment-for-pediatric-episodic-migraine</guid>
<pubDate>Wed, 04 Feb 2026 13:05:00 GMT</pubDate>
<description>Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg. With this approval, PrAJOVY® becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for eligible pediatric patients, marking a meaningful advancement</description>
</item>
<item>
<title>Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-canada-announces-strategic-partnership-with-novartis-canada-to-relaunch-mayzentr-for-multiple-sclerosis-patients-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-canada-announces-strategic-partnership-with-novartis-canada-to-relaunch-mayzentr-for-multiple-sclerosis-patients-in-canada</guid>
<pubDate>Mon, 02 Feb 2026 13:05:00 GMT</pubDate>
<description>Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada.</description>
</item>
<item>
<title>Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-innovative-portfolio-and-consistent-execution-of-pivot-to-growth-strategy-deliver-third-consecutive-year-of-growth-pipeline-positioned-to-unlock-significant-value-potential</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-innovative-portfolio-and-consistent-execution-of-pivot-to-growth-strategy-deliver-third-consecutive-year-of-growth-pipeline-positioned-to-unlock-significant-value-potential</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC</description>
</item>
<item>
<title>AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/ajovy-fremanezumab-vfrm-significantly-reduced-220200721</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/ajovy-fremanezumab-vfrm-significantly-reduced-220200721</guid>
<pubDate>Wed, 14 Jan 2026 22:02:00 GMT</pubDate>
<description>AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in pediatric patients with episodic migraine.1The U.S. Food and Drug Administration (FDA) approved AJOVY in August 2025 for the prevent</description>
</item>
<item>
<title>Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation</guid>
<pubDate>Sun, 11 Jan 2026 23:00:00 GMT</pubDate>
<description>Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis,</description>
</item>
<item>
<title>Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/royalty-pharma-and-teva-enter-agreement-to-accelerate-development-of-potential-treatment-for-vitiligo</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/royalty-pharma-and-teva-enter-agreement-to-accelerate-development-of-potential-treatment-for-vitiligo</guid>
<pubDate>Sun, 11 Jan 2026 22:15:00 GMT</pubDate>
<description>Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalt</description>
</item>
<item>
<title>Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-royalty-pharma-enter-agreement-to-accelerate-development-of-potential-treatment-for-vitiligo</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-and-royalty-pharma-enter-agreement-to-accelerate-development-of-potential-treatment-for-vitiligo</guid>
<pubDate>Sun, 11 Jan 2026 22:00:00 GMT</pubDate>
<description>Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pha</description>
</item>
<item>
<title>Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Mon, 05 Jan 2026 21:30:00 GMT</pubDate>
<description>TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archiv</description>
</item>
<item>
<title>S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/sandp-global-ratings-upgrades-teva-to-bb-amid-strong-execution-of-pivot-to-growth-strategy-moodys-ratings-agency-revises-outlook-to-positive</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/sandp-global-ratings-upgrades-teva-to-bb-amid-strong-execution-of-pivot-to-growth-strategy-moodys-ratings-agency-revises-outlook-to-positive</guid>
<pubDate>Wed, 24 Dec 2025 13:36:00 GMT</pubDate>
<description>The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a s</description>
</item>
<item>
<title>Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/alvotech-and-teva-secure-us-settlement-date-for-avt06-a-proposed-biosimilar-to-eylear</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/alvotech-and-teva-secure-us-settlement-date-for-avt06-a-proposed-biosimilar-to-eylear</guid>
<pubDate>Fri, 19 Dec 2025 08:40:00 GMT</pubDate>
<description>According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Ind</description>
</item>
<item>
<title>Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026</title>
<link>https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-host-conference-call-to-discuss-fourth-quarter-2025-financial-results-at-8-am-et-on-january-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/teva-pharmaceutical-industries-ltd/news/teva-to-host-conference-call-to-discuss-fourth-quarter-2025-financial-results-at-8-am-et-on-january-28-2026</guid>
<pubDate>Fri, 12 Dec 2025 21:30:00 GMT</pubDate>
<description>TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc</description>
</item>
</channel>
</rss>